Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own0.60% Shs Outstand49.78M Perf Week-13.18%
Market Cap190.16M Forward P/E- EPS next Y-0.93 Insider Trans-3.44% Shs Float49.78M Perf Month-2.30%
Income-36.70M PEG- EPS next Q-0.22 Inst Own72.50% Short Float5.52% Perf Quarter17.18%
Sales- P/S- EPS this Y-11.90% Inst Trans-0.02% Short Ratio3.82 Perf Half Y-40.96%
Book/sh1.61 P/B2.37 EPS next Y-3.30% ROA-66.50% Target Price16.06 Perf Year-23.60%
Cash/sh1.46 P/C2.62 EPS next 5Y- ROE-72.90% 52W Range2.36 - 10.54 Perf YTD33.10%
Dividend- P/FCF- EPS past 5Y-3.90% ROI- 52W High-63.76% Beta3.24
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low61.86% ATR0.26
Employees28 Current Ratio10.70 Sales Q/Q- Oper. Margin- RSI (14)41.26 Volatility7.01% 6.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.60% Profit Margin- Rel Volume0.68 Prev Close3.98
ShortableYes LT Debt/Eq0.00 EarningsMar 19 AMC Payout- Avg Volume719.06K Price3.82
Recom1.60 SMA20-8.80% SMA50-2.48% SMA200-26.71% Volume485,636 Change-4.02%
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Feb-27-19Downgrade Mizuho Buy → Neutral $13 → $5
Feb-06-19Initiated Leerink Partners Outperform $10
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Mar-19-19 08:46AM  Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options Zacks
Mar-11-19 09:57AM  Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings Zacks
09:55AM  Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing? Zacks
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results GlobeNewswire
Mar-06-19 07:30AM  Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy GlobeNewswire
Mar-05-19 02:51PM  Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why Benzinga +6.74%
07:30AM  Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference GlobeNewswire
Feb-26-19 03:31PM  Main Line biopharm CEO stepping down American City Business Journals
09:00AM  Marinus Announces Leadership Transition GlobeNewswire
Feb-20-19 07:30AM  Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference GlobeNewswire
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace -7.92%
Feb-05-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-30-19 07:35AM  New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-25-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.13%
Dec-22-18 01:54AM  Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS) Insider Monkey
Dec-13-18 12:25PM  Marinus Pharmaceuticals plans $45M stock sale American City Business Journals -11.88%
Dec-12-18 08:26PM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -17.45%
04:12PM  Here's Why Marinus Pharmaceuticals Is Sinking Today Motley Fool
08:07AM  The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel Benzinga
Dec-11-18 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Dec-10-18 12:50PM  Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials Benzinga
07:30AM  Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression GlobeNewswire
Dec-04-18 07:30AM  Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients GlobeNewswire -8.13%
Nov-19-18 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES GlobeNewswire
Nov-16-18 11:56AM  Granite Point Capitals Returns, AUM, and Holdings Insider Monkey
Nov-06-18 08:37AM  Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock? Zacks
07:30AM  Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-29-18 07:36AM  Marinus Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results GlobeNewswire
Oct-10-18 07:30AM  Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance GlobeNewswire -13.32%
Oct-09-18 04:48PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Oct-05-18 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -10.82%
Sep-28-18 02:28PM  What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Sep-25-18 07:30AM  Marinus Completes Enrollment in its Magnolia Postpartum Depression Study GlobeNewswire
Sep-24-18 10:30AM  Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market ACCESSWIRE
Sep-20-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 04:15PM  Marinus Pharmaceuticals to Present at the Baird Healthcare Conference GlobeNewswire
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-07-18 07:30AM  Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 02:48PM  Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today Motley Fool -13.02%
09:14AM  Marinus Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-21-18 08:44AM  Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga
Jul-16-18 07:05AM  Free Technical Research on Marinus Pharma and Three More Biotech Equities ACCESSWIRE
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch
Jul-11-18 10:52AM  Pfizer Doesn't Look Fundamentally or Technically Strong TheStreet.com
Jun-27-18 08:25AM  Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 07:30AM  Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index GlobeNewswire
Jun-19-18 07:30AM  Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder GlobeNewswire
Jun-15-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
07:55AM  Free Technical Reports on MannKind and Three Additional Biotech Equities ACCESSWIRE
Jun-06-18 03:43PM  Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation Benzinga +14.09%
May-30-18 07:30AM  Marinus Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire +5.32%
May-29-18 07:30AM  Mayo Clinic-Backed NMTC Could Be Worth 3X This Year ACCESSWIRE
May-24-18 11:34AM  Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today Motley Fool +15.11%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-14-18 07:30AM  Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference GlobeNewswire
May-11-18 08:25AM  Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
May-02-18 09:33AM  Marinus Pharmaceuticals: 1Q Earnings Snapshot Associated Press +5.33%
07:30AM  Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results GlobeNewswire
Mar-08-18 07:30AM  Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-06-18 04:14PM  Biotech Jumps After Rival Pushes Back Depression Drug Tests Investor's Business Daily -13.71%
12:58PM  Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today Motley Fool
08:01AM  Marinus Pharma shares slide 14% premarket after company posts wider-than-expected loss MarketWatch
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results GlobeNewswire
Feb-23-18 02:13PM  Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Feb-07-18 08:00AM  Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab Future Expectations, Projections Moving into 2018 GlobeNewswire +5.64%
07:30AM  Marinus Pharmaceuticals to Attend Upcoming Investor Conferences GlobeNewswire
Jan-03-18 06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
Dec-28-17 09:01AM  Key Risks Facing Marinus Pharmaceuticals in December 2017 Market Realist +8.89%
07:32AM  How Do Marinus Pharmaceuticals Financials Look? Market Realist
Dec-27-17 12:45PM  Ganaxalone Faces Stiff Competition from Other Drugs under Development Market Realist
11:15AM  Why Ganaxalone Is a Promising Drug Candidate Market Realist
09:41AM  What Analysts Recommend for Marinus Pharmaceuticals in December Market Realist
Dec-21-17 07:58AM  [$$] Bain Makes Bank in Two Rebounding Biotechs Barrons.com
Dec-18-17 04:42PM  Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today Motley Fool -9.70%
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-15-17 08:20AM  Todays Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals ACCESSWIRE -15.43%
Dec-14-17 01:07PM  Here's Why Marinus Pharmaceuticals Is Soaring Today Motley Fool +15.47%
Dec-13-17 07:30AM  Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index GlobeNewswire +9.63%
Dec-08-17 08:34AM  Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News Benzinga -9.03%
Dec-07-17 04:32PM  Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday Motley Fool +39.58%
Nov-16-17 08:10AM  Market Trends Toward New Normal in Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and Charles Schwab Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-10-17 08:10AM  Todays Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc. ACCESSWIRE
Nov-09-17 12:40PM  2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why. Motley Fool +14.14%
Oct-31-17 07:39AM  Marinus Pharmaceuticals posts 3Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-30-17 02:21PM  Are Marinus Pharmaceuticals Incs (MRNS) Interest Costs Too High? Simply Wall St. -5.34%
Sep-21-17 04:01PM  Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-19-17 04:01PM  Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriters option to purchase additional shares GlobeNewswire
Sep-15-17 07:30AM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-14-17 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks -8.19%
08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries ACCESSWIRE
Sep-11-17 10:35AM  Marinus Pharma Wins Big With Mid-Stage Epilepsy Study 24/7 Wall St. +33.01%
07:30AM  Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone GlobeNewswire
Aug-15-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation ACCESSWIRE
Aug-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics ACCESSWIRE
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cashman Christopher MichaelCEOMar 18Option Exercise1.0431,66232,928271,423Mar 20 05:57 PM
Smith Edward FCFOJan 29Sale3.062,4927,62644,308Jan 30 04:08 PM
Cashman Christopher MichaelCEOJan 28Sale3.138,14225,484239,761Jan 30 04:09 PM